Abstract:To achieve targeted, truly systemic therapeutic gene delivery to tumors, we exploited the observation that infection by a retrovirus proceeds initially through a non-specific adsorption stage prior to envelope-receptor recognition/internalization. Antigen specific, primary murine OT-1 T cells can be incubated in vitro with retroviral stocks which adhere to the cell surface. In vitro, virus can be handed off to target cells upon co-culture with the T cells, dependent upon cell contact, envelope/receptor interactions and local heparanase expression as provided by T cell activation upon encounter of antigen (ovalbumin) by the OT-1 T cells. Retroviral particles, pre-adsorbed to the surface of OT-1 T cells in vitro, were available for hand off in vivo to B16ova tumors distant from the site of T cell injection at high enough concentrations for therapeutic levels of gene transfer to occur. We have now delivered a variety of therapeutic genes to tumors, including HSVtk, IL-12 and the chemokine CCL-21. Pre- adsorption of vectors encoding each of these genes has led to therapeutic benefits in terms of direct local cell killing (HSVtk in combination with lymphodepletion), generation of potent immunizing activity (IL-12) and significant enhancement of the efficacy of subsequent doses of adoptively transferred, unmodified T cells (CCL-21). We have also characterized a second pathway by which viral particles expressing no envelope (BALD particles) can be handed off from T cells dependent upon T cell activation. Release of viral particles from the T cell surface coincides with the penetration of perforin-containing cytotoxic vesicles from the antigen activated T cells. The endosomolytic properties of perforin promote release of these viral particles from the endosome and, in situations where direct T cell killing does not occur, the virus goes onto to generate a productive infection. Thus, T cell mediated delivery of MLV core particles can be used to deliver therapeutic retroviral vectors in vivo using targeting at the level of T cell activation, thereby dispensing with the need to target viral envelopes. We have also investigated the possibilities of using antigen specific T cells to deliver replication competent viruses to tumors both in vitro and in vivo. In particular, we have demonstrated that replication competent Vesicular Stomatitis virus expressing GFP can be used to load OT-1 T cells. The virus infects these T cells only at very low levels and does not kill them. However, the T cells produce VSV particles at appreciable levels 48-72 hours post loading suggesting that they may be able to carry the viruses to tumors in vivo and lead to productive infection following intratumoral T cell accumulation. Therefore, the protection, concentration, and targeted delivery of viruses by T cell carriers offers great potential for the delivery of vector stocks into the circulation of patients. By careful selection of the virus, and therapeutic gene that is used, significant synergy can be achieved over the use of virotherapy, or adoptive T cell therapy, alone.

653. the Controlled Transgene Expression in Oncolytic Adenoviral Vectors with Major Late Promoter for Therapy of Cancer

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

A Novel Single Tetracycline-Regulative Adenoviral Vector for Tumor-Specific Bax Gene Expression and Cell Killing in Vitro and in Vivo

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect

Construction of Htert and Cox-2 Dependent Oncolytic Adenovirus

Gene-viral Vectors: a Promising Way to Target Tumor Cells and Express Anticancer Genes Simultaneously.

Construction and Characterization of Oncolytic Adenovirus Controlled under Heat Shock Protein70 Gene Promoter*

Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy

A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression

Construction of a Novel Oncolytic Adenoviral Vector and Its Biological Characteristics

Oncolytic Adenovirus Programmed by Synthetic Gene Circuit for Cancer Immunotherapy

Construction of Tumor-specific Oncolytic Adenovirus Vector and its Primary Study on Selective Expression in Tumor Cells

[Advances in research on oncolytic adenoviruses in tumor therapy]

A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.

Tetracycline controlled DT/VEGF system gene therapy mediated by adenovirus vector

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

812. Cellular Delivery of Gene Therapy Vectors

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

A Novel Htert Promoter-Driven E1a Therapeutic for Ovarian Cancer

[Gene Expression of Tumor Cells Both in Vitro and in Vivo Enhanced by Integrin-Targeting Adenovirus Vector].

Tumor-specific transcriptional targeting of suicide gene therapy